| Name | Title | Contact Details |
|---|
We are a thriving community bank that prides ourselves on hard work, friendly and knowledgeable customer service, and convenient, local banking. Since November of 2000, BCB has been offering a wide range of loans, deposit products, and retail and commercial banking services. As of today, there are twenty-seven branches expanding across the NJ & NY areas and one administrative office located in Bayonne, NJ. BCB continues to find ways of improving our services for an enjoyable and hassle-free banking experience seven days a week. We are a member of the FDIC and an Equal Housing Lender.
Smartchoice.pk is Pakistans leading insurance marketplace. We have helped thousands of individuals and business find best insurance plans. We work with Pakistans top insurance companies including EFU, Jubilee, Adamjee, IGI, TPL, UIC Pak Qatar Genreral Takaful offering customised plans for business and individuals to instantly purchase policy online For Business: Group Health Insurance Group Life Insurance For Individuals Travel Insurance* Health Insurance* Car Insurance Term Life Insurance Personal Accident Insurance *Pay online and get insured instantly. We have been covered by Dawn, British Council UK, Tribune, Insurance Post UK
Fatima Group is one of the largest business conglomerates in Pakistan operating in diversified sectors like Fertilizers, Textiles, Sugar, Energy, Packaging, Mining & Trading of commodities. Established in 1936 with trading of commodities and gradually entered into the manufacturing of various products. The Group has a success story spread over seven decades, expanding its horizon from trading to manufacturing. With an annual turnover of over 80 billion PKR and more than 6,300 employees, Fatima Group plays an important role in the economic development of the country.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.